Research Article
Prognostic Analysis for Cardiogenic Shock in Patients with Acute Myocardial Infarction Receiving Percutaneous Coronary Intervention
Table 2
Demography of study population and medications during admission in patients with and without shock.
| | Characteristics | Shock (%) | Without shock (%) | value |
| | Gender | | | 0.996 | | Male | 41 (77.4) | 332 (77.4) | | | Female | 12 (22.6) | 97 (22.6) | | | STEMI | | | | | Yes | 36 (67.9) | 184 (42.9) | | | No | 17 (32.1) | 245 (57.1) | | | Diabetes | | | 0.597 | | Yes | 23 (43.4) | 170 (39.6) | | | No | 30 (56.6) | 259 (60.4) | | | Hypertension | | | <0.00 | | Yes | 13 (24.5) | 225 (52.4) | | | No | 40 (75.5) | 204 (47.6) | | | CKD | | | 0.662 | | Yes | 28 (52.8) | 213 (49.7) | | | No | 25 (47.2) | 216 (50.3) | | | Hypercholesterolemia | | | 0.125 | | Yes | 22 (41.5) | 226 (52.7) | | | No | 31 (58.5) | 203 (47.3) | | | Current smoker | | | 0.981 | | Yes | 23 (43.4) | 185 (43.2) | | | No | 30 (56.6) | 243 (56.8) | | | Stroke history | | | 0.673 | | Yes | 4 (7.5) | 26 (6.1) | | | No | 49 (92.5) | 403 (93.9) | | | CABG history | | | 0.369 | | Yes | 1 (1.9) | 3 (0.7) | | | No | 52 (98.1) | 426 (99.3) | | | Aspirin | | | 0.559 | | Yes | 50 (94.3) | 395 (92.1) | | | No | 3 (5.7) | 34 (7.9) | | | P2Y12 inhibitors | | | | | Yes | 53 (100) | 397 (92.5) | | | No | 0 | 32 (7.5) | | | Diuretics | | | 0.226 | | Yes | 10 (18.9) | 114 (26.6) | | | No | 43 (81.1) | 315 (73.4) | | | Beta-blockers | | | 0.549 | | Yes | 24 (45.3) | 213 (49.7) | | | No | 29 (54.7) | 216 (50.3) | | | CCB | | | | | Yes | 3 (5.7) | 85 (19.8) | | | No | 50 (94.3) | 344 (80.2) | | | ACEI | | | 0.247 | | Yes | 15 (28.3) | 156 (36.4) | | | No | 38 (71.7) | 273 (63.6) | | | ARB | | | 0.090 | | Yes | 5 (9.4) | 81 (18.9) | | | No | 48 (90.6) | 348 (81.1) | | | Statins | | | | | Yes | 14 (26.4) | 176 (41.0) | | | No | 39 (73.6) | 253 (59.0) | | | Fibrate | | | 0.845 | | Yes | 2 (3.8) | 14 (3.3) | | | No | 51 (96.2) | 415 (96.7) | |
|
|
Previous MI: history of previous myocardial infarction; CABG history: history of coronary artery bypass graft; CKD: chronic kidney disease; P2Y12 inhibitor: P2Y12 receptor inhibitor of platelet; CCB: calcium channel blocker; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker. Significant.
|
